Press release
DRSplus, the newest addition to CenterVue's family of fundus imaging devices, has been approved by the
First launched in 2011, CenterVue's widely successful DRS device will gradually be replaced by the DRSplus model which is especially well suited for the evaluation of diabetic retinopathy. The DRSplus is a confocal fundus imaging system which uses white LED illumination to produce TrueColor and detail-rich images, setting a new effective and efficient standard for fundus imaging. DRSplus uses the TrueColor confocal technology, which up until now has only been available in other CenterVue products. Moreover, the diameter of the pupil being imaged may now be smaller, which increases the likelihood of successful imaging of all patients. DRSplus is fast and fully automated.
"We have carefully listened to our customers and used the feedback received in the R&D process of the new DRSplus fundus imaging device. We believe that we have developed the best product on the market in this segment, which allows faster and more reliable high-quality fundus imaging. With the marketing authorizations the product has been granted, we can now launch the product in both
The main tools for the detection, diagnosis and on-treatment monitoring of glaucoma are intraocular pressure measurement (tonometry), fundus imaging and visual field test (perimetry).
timo.hilden@revenio.fi
www.revenio.fi
DISTRIBUTION:
Major news outlets
www.revenio.fi
The key principles of
In 2018,
https://news.cision.com/revenio-group-oyj/r/revenio-s-new-fundus-imaging-device-authorized-for-sale-in-the-united-states-and-europe,c2982099
https://mb.cision.com/Main/17714/2982099/1155459.pdf
(c) 2019 Cision. All rights reserved., source